The in vitro diagnostics (IVD) market, already valued at USD $102 billion in 2024, is on the brink of transformation, driven by the surge in liquid biopsy technologies. With a predicted CAGR of 5.2%, this segment is poised to reach USD $132 billion by 2029, fueled by the escalating prevalence of cancer, the fastest-growing market segment.

Why It Matters

By 2040, cancer diagnoses are expected to escalate to 29.5 million cases annually, with deaths reaching 16.4 million, underscoring the critical need for early detection. The oncology IVD segment, projected to grow by 48% by 2033, highlights the anticipated advancements in technologies aimed at improving cancer diagnoses.

State of Play

• Liquid biopsy technologies are transforming the landscape of cancer care. By integrating Next-Generation Sequencing (NGS) and Artificial Intelligence (AI), they are setting new standards for precision in targeted therapy.
• This approach surpasses traditional biopsy methods by offering enhanced sensitivity and specificity, marking a significant leap forward in diagnostic accuracy and the management of cancer treatments.

Regulatory Milestones

Technological developments and regulatory approvals have fuelled clinical and investor momentum towards liquid biopsies, positioning them as viable alternatives to conventional tissue biopsies.

• The landmark 2020 FDA approvals of two NGS-coupled liquid biopsies, Guardant360 CDx and FoundationOne Liquid CDx marks a significant stride in cancer care, representing a breakthrough in offering detailed genomic insights for patient care.

Deep Dive

The liquid biopsy landscape is vibrant with strategic investments and mergers, reflecting robust market optimism for its revolutionary impact on cancer diagnostics.

• Precede Biosciences secured a significant $57M from leading investors including 5AM Ventures and Lilly Asia Ventures, marking a pivotal moment for its liquid biopsy technology.

• Mercy BioAnalytics raised $41M in Series A funding, driving forward its cutting-edge extracellular vesicle technology for early cancer detection.

• Quest Diagnostics enhanced its diagnostic capabilities with the strategic acquisition of Haystack Oncology for up to $450M, integrating cutting-edge liquid biopsy technology into its extensive diagnostics portfolio.

• 4D Lifetec partners with Xlife Sciences, selling a 20% stake for $25.9M, merging AI diagnostics with innovative biomarker research for early detection.

Innovation at the Fore

Although still in the early stages of development, innovations in liquid biopsy technologies are poised to significantly improve the detection of tumors.

• Dxcover has secured a $12M Series A for its AI platform, which detects cancer biomarkers in blood, offering a novel approach for brain cancer diagnostics where traditional diagnostic methods are lacking.
• Researchers at UC Santa Cruz are significantly advancing cancer diagnostics by analyzing protein coding as well as non-coding RNA in the blood.
• Researchers from MIT and Harvard have developed “priming agents” to enhance the sensitivity of liquid biopsies, enabling more accurate diagnoses and the earlier detection of tumors.

The Bottom Line

The landscape of liquid biopsy is rapidly evolving and is transforming cancer diagnosis. Promising to improve patient outcomes through early detection, it’s gaining recognition for its critical role in personalized medicine. However, this technological disruption extends beyond cancer, offering the potential for wide-ranging applications across various diseases.

Developing Diagnostics

Acquire insights into the process of developing a diagnostic, identifying its FDA designation, and understanding the regulatory requirements associated with its Class designation within a single 40-minute session. This content is covered in the on-demand course “Diagnostic Development Primer” offered by Biotech Primer. Sign up today!